checkAd
    Startseite > Aktien > Annovis Bio > Nachrichten
    Annovis Bio Aktie
    6,8100
     
    USD
    +3,97 %
    +0,2600 USD
    Letzter Kurs 02:04:00 NYSE
    6,8100
     
    USD
    300 STK
    Geldkurs 03.06.24
    6,8800
     
    USD
    4.600 STK
    Briefkurs 03.06.24
    ISIN: US03615A1088 · WKN: A2PNH2 · SYM: ANVS · USA

    Neueste Nachrichten

    Annovis Announces New Publication in a Peer-Reviewed Journal
    21.05.24 · globenewswire · Annovis Bio
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
    17.05.24 · Business Wire (engl.) · Annovis Bio
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
    17.05.24 · Business Wire (engl.) · Annovis Bio
    The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
    16.05.24 · Business Wire (engl.) · Annovis Bio
    Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
    13.05.24 · globenewswire · Annovis Bio
    Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
    09.05.24 · globenewswire · Annovis Bio
    Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
    06.05.24 · globenewswire · Annovis Bio
    Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
    29.04.24 · globenewswire · Annovis Bio
    Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
    02.04.24 · globenewswire · Annovis Bio
    Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
    01.04.24 · globenewswire · Annovis Bio
    Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
    20.03.24 · globenewswire · Annovis Bio
    Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024
    27.02.24 · globenewswire · Annovis Bio